Urgent

Pulmonary arterial hypertension (PAH) — chronic management (WHO Group 1)

pulmonary-arterial-hypertension · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

WHO Group 1 pre-capillary pulmonary hypertension (idiopathic, heritable, connective-tissue-disease-associated, drug/toxin, congenital heart disease, portopulmonary, etc.) — distinct from the acute PH crisis and cor pulmonale entries. Diagnosis requires right heart catheterisation; treatment is risk-stratified PAH-specific vasodilator therapy in an expert centre. Early recognition and referral change outcome.

Red flags

  • Syncope, chest pain, or signs of decompensated right heart failure (high-risk features)
  • Rapidly progressive breathlessness / falling 6MWD / rising NT-proBNP
  • Hypotension, low cardiac output (impending PH crisis -> dedicated pathway)
  • Pregnancy (very high maternal mortality)
  • Haemoptysis

Assessment

Differential diagnosis

  • Group 2 PH (left heart disease) - commonest overall
  • Group 3 PH (lung disease/hypoxia: COPD, ILD)
  • Group 4 PH (chronic thromboembolic - CTEPH; potentially curable)
  • Group 5 PH (multifactorial)
  • Other causes of breathlessness: heart failure, anaemia, deconditioning

Investigations

  • Transthoracic echocardiography — screening: estimate PASP, RV size/function, exclude left heart disease
  • Right heart catheterisation — REQUIRED to confirm (mean PAP >20 mmHg, PAWP <=15 mmHg, PVR >2 Wood units for pre-capillary PH)
  • V/Q scan to exclude CTEPH (do NOT rely on CTPA alone to exclude it)
  • Pulmonary function tests + DLCO, overnight oximetry, HRCT (exclude lung disease)
  • Connective-tissue-disease serology (ANA, anti-centromere, Scl-70), HIV, liver function/portal hypertension assessment
  • ECG, NT-proBNP, 6-minute walk distance, WHO functional class (for risk stratification)
  • Vasoreactivity testing at RHC (idiopathic/heritable/drug-induced) to identify calcium-channel-blocker responders

Management

  • Suspect PAH in unexplained exertional breathlessness with RV strain signs; screen with echo
  • REFER early to a specialist pulmonary hypertension centre — do not start PAH drugs empirically
  • Confirm diagnosis and group with right heart catheterisation; exclude CTEPH (V/Q) and left heart/lung disease
  • Risk-stratify (low/intermediate/high) using a multiparameter tool (WHO class, 6MWD, NT-proBNP, haemodynamics)
  • General measures: supervised exercise/rehab, diuretics for RV volume overload, oxygen if hypoxaemic, treat iron deficiency, contraception counselling (pregnancy is high-risk), vaccination
  • A minority of vasoreactive idiopathic patients: high-dose calcium channel blockers
  • Most low/intermediate risk (no cardiopulmonary comorbidity): initial dual oral therapy - an endothelin receptor antagonist + a PDE5 inhibitor
  • High-risk patients: add a parenteral prostacyclin pathway agent (triple therapy) up front
  • Escalate and reassess at follow-up aiming for a low-risk status; consider lung transplantation referral if inadequate response
  • For confirmed CTEPH refer for pulmonary endarterectomy / balloon pulmonary angioplasty (potentially curative)

Drugs & doses

Ambrisentan 5-10 mg PO once daily (endothelin receptor antagonist) — teratogenic, monthly pregnancy testing [verify local programme]
Tadalafil 40 mg PO once daily (PDE5 inhibitor); or sildenafil 20 mg PO three times daily
Macitentan 10 mg PO once daily (alternative ERA)
Selexipag oral prostacyclin receptor agonist, titrated; or parenteral epoprostenol/treprostinil for high-risk disease (specialist) [verify dose/protocol]
High-dose calcium channel blocker (e.g. nifedipine/amlodipine/diltiazem) ONLY in confirmed vasoreactive responders [verify dose]
Diuretic e.g. furosemide for RV failure/volume overload [verify dose]
Supplemental oxygen to keep SpO2 >=90-92% if hypoxaemic

Disposition

Specialist pulmonary hypertension centre for diagnosis and therapy. Admit decompensated right heart failure / crisis to HDU-ICU. Lifelong specialist follow-up with periodic risk re-stratification.

Complications & pitfalls

  • Progressive right ventricular failure and death
  • Pulmonary hypertensive crisis
  • Arrhythmias (atrial flutter/fibrillation poorly tolerated)
  • Drug side-effects: hepatotoxicity (ERAs), hypotension, line infection (parenteral prostacyclins)
  • Maternal death in pregnancy

Exam pearls

  • PAH requires right heart catheterisation to diagnose and must be managed in an expert pulmonary hypertension centre — refer early (2022 ESC/ERS PH guidelines).
  • ALWAYS exclude CTEPH with a V/Q scan — it is potentially curable by pulmonary endarterectomy and a normal V/Q effectively rules it out.
  • Initial combination therapy (ambrisentan + tadalafil, or macitentan + tadalafil) is recommended for most low/intermediate-risk patients without cardiopulmonary comorbidity (AMBITION; Class I-B).
  • Only true vasoreactive responders benefit from calcium channel blockers; giving CCBs to non-responders is dangerous.
  • The 2024 World Symposium (WSPH) updated the treatment algorithm and lowered the haemodynamic thresholds (mPAP >20, PVR >2 WU) — verify against the version in local use.
  • Pregnancy carries very high mortality in PAH — advise reliable contraception.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.